AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19065856 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained spatial attention
Number of subjects: 0
Study 19065856 — intervention group
Group type: EXPERIMENTAL
Intervention: Test stimuli at peri‐threshold, intermediate contrast levels
Number of subjects: 0
Study 16841623 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion XL (300-450 mg/day)
Number of subjects: 276
Study 16841623 — intervention group
Group type: EXPERIMENTAL
Intervention: Escitalopram (10-20 mg/day)
Number of subjects: 276
Study 16841623 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 276
Study 12801312 — intervention group
Group type: EXPERIMENTAL
Intervention: Ozone (0.2 ppm) exposure for 2 hours
Number of subjects: 0
Study 12801312 — intervention group
Group type: COMPARATOR
Intervention: Filtered air exposure for 2 hours
Number of subjects: 0
Study 10327874 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in sodium intake of 118 mmol
Number of subjects: 114
Study 10327874 — intervention group
Group type: EXPERIMENTAL
Intervention: Reduction in sodium intake
Number of subjects: 114
Study 7547043 — intervention group
Group type: EXPERIMENTAL
Intervention: 4% amethocaine gel
Number of subjects: 94
Study 7547043 — intervention group
Group type: COMPARATOR
Intervention: 5% EMLA cream
Number of subjects: 94
Study 1687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline
Number of subjects: 250
Study 1687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Noxiptilin
Number of subjects: 250
Study 1687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 250
Study 1687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Dibenzepin
Number of subjects: 250
Study 1687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Clomipramine
Number of subjects: 250
Study 1687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 250
Study 1687987 — intervention group
Group type: EXPERIMENTAL
Intervention: Nomifensine
Number of subjects: 250
Study 7046930 — intervention group
Group type: EXPERIMENTAL
Intervention: melphalan
Number of subjects: 31
Study 7046930 — intervention group
Group type: COMPARATOR
Intervention: radioactive phosphorus
Number of subjects: 31
Study 30644312 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg seltorexant
Number of subjects: 20
Study 30644312 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg seltorexant
Number of subjects: 20
Study 30644312 — intervention group
Group type: EXPERIMENTAL
Intervention: 40 mg seltorexant
Number of subjects: 20
Study 30644312 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28183335 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation (50,000 IU weekly for 3 weeks, then 2000 IU daily until 1 year post ART initiation)
Number of subjects: 4000
Study 28183335 — intervention group
Group type: COMPARATOR
Intervention: Placebo regimen
Number of subjects: 4000
Study 28183335 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 supplementation
Number of subjects: 4000
Study 26843154 — intervention group
Group type: EXPERIMENTAL
Intervention: Soy isoflavones (80 mg aglycone equivalents)
Number of subjects: 28
Study 26843154 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 28
Study 26843154 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercially produced S-(−)equol (40 mg)
Number of subjects: 28
Study 24215991 — intervention group
Group type: EXPERIMENTAL
Intervention: Bilateral support to walk
Number of subjects: 365
Study 24215991 — intervention group
Group type: EXPERIMENTAL
Intervention: No walking impairment
Number of subjects: 365
Study 24215991 — intervention group
Group type: EXPERIMENTAL
Intervention: Impaired walking, no aid
Number of subjects: 365
Study 24215991 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 365
Study 22585228 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 25 mg/day for 5 days
Number of subjects: 102
Study 22585228 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 100 mg/day for 5 days
Number of subjects: 102
Study 22585228 — intervention group
Group type: EXPERIMENTAL
Intervention: Rifaximin 100 mg/day for 2 days
Number of subjects: 102
Study 22585228 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study 20067456 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupropion SR (150 mg twice daily)
Number of subjects: 234
Study 16926046 — intervention group
Group type: EXPERIMENTAL
Intervention: Prenatal ultrasound scanning
Number of subjects: 0
Study 15668857 — intervention group
Group type: EXPERIMENTAL
Intervention: Clarithromycin
Number of subjects: 473
Study 15668857 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 473
Study 12474512 — intervention group
Group type: EXPERIMENTAL
Intervention: Suture repair (Group I) for hernias between 5-25 cm²
Number of subjects: 2300
Study 12474512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh implantation (sublay) (Group II) for hernias larger than 25 cm²
Number of subjects: 2300
Study 12474512 — intervention group
Group type: EXPERIMENTAL
Intervention: Mesh implantation (onlay) (Group II) for hernias larger than 25 cm²
Number of subjects: 2300
Study 12474512 — intervention group
Group type: EXPERIMENTAL
Intervention: Laparoscopic approach (Group II) for hernias larger than 25 cm²
Number of subjects: 2300
Study 9922309 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral budesonide, 6 mg daily
Number of subjects: 129
Study 9922309 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 129
Study 7570133 — intervention group
Group type: EXPERIMENTAL
Intervention: Moclobemide
Number of subjects: 32
Study 7570133 — intervention group
Group type: COMPARATOR
Intervention: Imipramine
Number of subjects: 32
Study 2270057 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2ml/kg alcohol with exteroceptive contextual cues (AL-EXPT)
Number of subjects: 40
Study 2270057 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.2ml/kg alcohol in a context not normally associated with alcohol (AL-UNEXPT)
Number of subjects: 40
Study 2270057 — intervention group
Group type: COMPARATOR
Intervention: Nonalcoholic beverage believed to be alcohol (placebo)
Number of subjects: 40
Study 2270057 — intervention group
Group type: COMPARATOR
Intervention: Juice in the alcohol-unexpected context
Number of subjects: 40
Study 7366836 — intervention group
Group type: EXPERIMENTAL
Intervention: Metrizamide (Amipaque)
Number of subjects: 308
Study 7366836 — intervention group
Group type: COMPARATOR
Intervention: Meglumine metrizoate (Isopaque Cerebral)
Number of subjects: 308
Study 30696443 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behavioural therapy (CBT)
Number of subjects: 57
Study 30696443 — intervention group
Group type: COMPARATOR
Intervention: Occlusal appliance (OA)
Number of subjects: 57
Study 28106611 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fentanyl
Number of subjects: 16
Study 28106611 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fentanyl
Number of subjects: 16
Study 28106611 — intervention group
Group type: COMPARATOR
Intervention: Control (baseline)
Number of subjects: 16
Study 26027628 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase (TNK) post-amendment (50% reduction in dose)
Number of subjects: 135
Study 26027628 — intervention group
Group type: COMPARATOR
Intervention: Standard dose tenecteplase (TNK) pre-amendment
Number of subjects: 135
Study 26027628 — intervention group
Group type: EXPERIMENTAL
Intervention: Half-dose tenecteplase (TNK) post-amendment
Number of subjects: 135
Study 24118794 — intervention group
Group type: EXPERIMENTAL
Intervention: Lowered endothelial function measured by peripheral arterial tonometry (PAT)
Number of subjects: 312
Study 24118794 — intervention group
Group type: EXPERIMENTAL
Intervention: HDL cholesterol
Number of subjects: 312
Study 24118794 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex, body mass index, current smoking
Number of subjects: 312
Study 24118794 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepwise multivariable regression model
Number of subjects: 312
Study 21889801 — intervention group
Group type: EXPERIMENTAL
Intervention: Ahmed‐FP7 valve
Number of subjects: 238
Study 21889801 — intervention group
Group type: COMPARATOR
Intervention: Baerveldt‐350 implant
Number of subjects: 238
Study 18783797 — intervention group
Group type: EXPERIMENTAL
Intervention: Infant Behavioral Assessment and Intervention Program (IBAIP)
Number of subjects: 176
Study 18783797 — intervention group
Group type: COMPARATOR
Intervention: Standard care (control)
Number of subjects: 176
Study 16740395 — intervention group
Group type: EXPERIMENTAL
Intervention: Group 1: 15 trials on 1 day
Number of subjects: 26
Study 16740395 — intervention group
Group type: COMPARATOR
Intervention: Group 2: 5 trials on each of three consecutive days
Number of subjects: 26
Study 16740395 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 26
Study 12971512 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - Group 1: intravenous loading dose of 140 mg/kg followed by 70 mg/kg every four hours for up to 18 doses
Number of subjects: 108
Study 12971512 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - Group 2: a single intravenous loading dose followed by oral NAC in the same amount as for Group 1
Number of subjects: 108
Study 12971512 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine (NAC) - Group 3: regimen identical to Group 1 except that oral NAC was administered after the first 24 hours
Number of subjects: 108
Study 12971512 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus artesunate
Number of subjects: 108
Study 10953124 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical resiniferatoxin (10 nM)
Number of subjects: 18
Study 10953124 — intervention group
Group type: COMPARATOR
Intervention: Placebo saline solution
Number of subjects: 18
Study 8630635 — intervention group
Group type: EXPERIMENTAL
Intervention: Meloxicam 7.5 mg once daily
Number of subjects: 336
Study 8630635 — intervention group
Group type: COMPARATOR
Intervention: Diclofenac 100 mg slow release once daily
Number of subjects: 336
Study 1442992 — intervention group
Group type: EXPERIMENTAL
Intervention: Depot leuprolide
Number of subjects: 270
Study 1442992 — intervention group
Group type: COMPARATOR
Intervention: Danazol
Number of subjects: 270
Study 6563534 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group (N = 42)
Number of subjects: 86
Study 6563534 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 44)
Number of subjects: 86
Study 3578733 — intervention group
Group type: EXPERIMENTAL
Intervention: Magill tracheal tubes
Number of subjects: 100
Study 3578733 — intervention group
Group type: COMPARATOR
Intervention: Mallinckrodt tracheal tubes
Number of subjects: 100
Study 29274118 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (DEX)
Number of subjects: 0
Study 29274118 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (PRED)
Number of subjects: 0
Study 29274118 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose methotrexate (HD-MTX)
Number of subjects: 0
Study 29274118 — intervention group
Group type: COMPARATOR
Intervention: Escalating doses of methotrexate (C-MTX)
Number of subjects: 0
Study 28566632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-caffeine green tea (≥500 mL/d, with theanine ca. 15 mg/d)
Number of subjects: 20
Study 28566632 — intervention group
Group type: COMPARATOR
Intervention: Placebo tea
Number of subjects: 20
Study 28566632 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-caffeine green tea
Number of subjects: 20
Study 25783756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy (CBT), 30 sessions
Number of subjects: 45
Study 25783756 — intervention group
Group type: COMPARATOR
Intervention: Healthy comparison subjects
Number of subjects: 45
Study 23065509 — intervention group
Group type: EXPERIMENTAL
Intervention: Chromosomal aberrations (specifically 6q deletions, trisomy 18, 13q deletions, 17p deletions, trisomy 4, 11q deletions)
Number of subjects: 174
Study 23065509 — intervention group
Group type: EXPERIMENTAL
Intervention: TP53 deletion
Number of subjects: 174
Study 23065509 — intervention group
Group type: EXPERIMENTAL
Intervention: Trisomy 12
Number of subjects: 174
Study 20505665 — intervention group
Group type: EXPERIMENTAL
Intervention: Posaconazole oral suspension (POS) 200 mg three times daily (t.i.d.)
Number of subjects: 0
Study 18378519 — intervention group
Group type: EXPERIMENTAL
Intervention: Active treatment (indapamide 1.5 mg sustained release)
Number of subjects: 3845
Study 16360877 — intervention group
Group type: EXPERIMENTAL
Intervention: High self‐efficacy and high negative incentive value
Number of subjects: 80
Study 16360877 — intervention group
Group type: EXPERIMENTAL
Intervention: Low self‐efficacy and high negative incentive value
Number of subjects: 80
Study 16360877 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive regulation of systolic and diastolic blood pressure and pulse pressure
Number of subjects: 80
Study 16360877 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived competence
Number of subjects: 80
Study 12745193 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with losartan 50 mg daily
Number of subjects: 55
Study 12745193 — intervention group
Group type: COMPARATOR
Intervention: Control diet with losartan 50 mg daily
Number of subjects: 55
Study 12745193 — intervention group
Group type: EXPERIMENTAL
Intervention: DASH diet with placebo
Number of subjects: 55
Study 12745193 — intervention group
Group type: COMPARATOR
Intervention: Control diet with placebo
Number of subjects: 55
Study 11310907 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol with EDTA
Number of subjects: 102
Study 11310907 — intervention group
Group type: COMPARATOR
Intervention: Propofol without EDTA
Number of subjects: 102
Study 8793606 — intervention group
Group type: EXPERIMENTAL
Intervention: Pantoprazole 40 mg tablet for 7 days
Number of subjects: 23
Study 8793606 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 7 days
Number of subjects: 23
Study 1627417 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential methotrexate and fluorouracil (MTX-5-FU) followed by leucovorin
Number of subjects: 737
Study 1627417 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen (TMX)
Number of subjects: 737
Study 1627417 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 737
Study 6744774 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (40 to 360 mg/day)
Number of subjects: 17
Study 6744774 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa (500 to 2500 mg/day)
Number of subjects: 17
Study 6744774 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 17
Study 6744774 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 17
Study 6744774 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Methyldopa
Number of subjects: 17
Study 31487806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) with Low-Fiber (LoFi) products
Number of subjects: 73
Study 31487806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP)
Number of subjects: 73
Study 31487806 — intervention group
Group type: EXPERIMENTAL
Intervention: High-Fiber (HiFi) intake
Number of subjects: 73
Study 31487806 — intervention group
Group type: COMPARATOR
Intervention: Maltodextrin (MD) with Low-Fiber (LoFi)
Number of subjects: 73
Study 31487806 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey Protein (WP) with High-Fiber (HiFi) products
Number of subjects: 73
Study 29069908 — intervention group
Group type: EXPERIMENTAL
Intervention: Initial nine-species-based selection of optical filters
Number of subjects: 31
Study 29069908 — intervention group
Group type: EXPERIMENTAL
Intervention: Bootstrap analysis based on the larger data set
Number of subjects: 31
Study 29069908 — intervention group
Group type: EXPERIMENTAL
Intervention: Filter selection using all 31 species
Number of subjects: 31
Study 29069908 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-rank hypothesis
Number of subjects: 31
Study 26440129 — intervention group
Group type: EXPERIMENTAL
Intervention: Point-of-care ultrasound
Number of subjects: 84
Study 26440129 — intervention group
Group type: COMPARATOR
Intervention: Consultative ultrasound
Number of subjects: 84
Study 24379136 — intervention group
Group type: EXPERIMENTAL
Intervention: Flu-Like Symptom Index (FLSI)
Number of subjects: 0
Study 22748820 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous aspirin (300 mg) within 90 min after alteplase treatment
Number of subjects: 642
Study 22748820 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment (alteplase without aspirin)
Number of subjects: 642
Study 19906503 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-care management intervention
Number of subjects: 7677
Study 17609331 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based physical therapy intervention
Number of subjects: 47
Study 17609331 — intervention group
Group type: COMPARATOR
Intervention: Clinic-based management
Number of subjects: 47
Study 16059679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense artery sign identified via maximum intensity projections
Number of subjects: 49
Study 16059679 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased density of the whole M1 segment with extension to M2
Number of subjects: 49
Study 16059679 — intervention group
Group type: EXPERIMENTAL
Intervention: Dense sylvian branch of the middle cerebral artery pattern
Number of subjects: 49
Study 16059679 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients without a demonstrable dense artery
Number of subjects: 49
Study 16059679 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with 7-10 points on the Alberta Stroke Early Programme Computed Tomography Score and a dense proximal MCA
Number of subjects: 49
Study 12244740 — intervention group
Group type: EXPERIMENTAL
Intervention: Product 1 (0.243% sodium fluoride with copolymer, tetrasodium pyrophosphate, and sodium tripolyphosphate in a silica base)
Number of subjects: 126
Study 12244740 — intervention group
Group type: EXPERIMENTAL
Intervention: Product 2 (0.243% sodium fluoride, baking soda and peroxide, tetrasodium pyrophosphate, and sodium tripolyphosphate in a silica base)
Number of subjects: 126
Study 12244740 — intervention group
Group type: COMPARATOR
Intervention: Product 3 (0.243% sodium fluoride in a silica base)
Number of subjects: 126
Study 11860782 — intervention group
Group type: EXPERIMENTAL
Intervention: Benazepril
Number of subjects: 1831
Study 8861829 — intervention group
Group type: EXPERIMENTAL
Intervention: PMEA (9-(2-phosphonylmethoxyethyl)adenine) administered intravenously at a dose of 1000 mg weekly for 11 weeks
Number of subjects: 10
Study 1731046 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (0.05, 0.10, 0.15 and 0.20 mg)
Number of subjects: 20
Study 1731046 — intervention group
Group type: COMPARATOR
Intervention: Saline placebo
Number of subjects: 20
Study 1731046 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone
Number of subjects: 20
Study 3937219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryoprecipitate from 30 donors (n = 14)
Number of subjects: 28
Study 3937219 — intervention group
Group type: COMPARATOR
Intervention: Stored plasma (n = 14)
Number of subjects: 28
Study 30586209 — intervention group
Group type: EXPERIMENTAL
Intervention: BRJ nitrate (8.1 mmol BRJ nitrate)
Number of subjects: 18
Study 30586209 — intervention group
Group type: EXPERIMENTAL
Intervention: BRJ nitrate
Number of subjects: 18
Study 30586209 — intervention group
Group type: COMPARATOR
Intervention: BRJ placebo
Number of subjects: 18
Study 29897851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride content, rapid rate of administration
Number of subjects: 1255
Study 29897851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.9% sodium chloride content, slow rate of administration
Number of subjects: 1255
Study 29897851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% sodium chloride content, rapid rate of administration
Number of subjects: 1255
Study 29897851 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.45% sodium chloride content, slow rate of administration
Number of subjects: 1255
Study 29897851 — intervention group
Group type: COMPARATOR
Intervention: All treatment groups
Number of subjects: 1255
Study 27132415 — intervention group
Group type: EXPERIMENTAL
Intervention: Piroxicam 10 mg/day on days 4-6 after IUI
Number of subjects: 260
Study 27132415 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 260
Study 23813113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lenses (ReSTOR SN6AD1, ReSTOR SN60D3, ReZoom NXG, Tecnis ZMA00)
Number of subjects: 180
Study 23813113 — intervention group
Group type: COMPARATOR
Intervention: Monofocal intraocular lens (Tecnis ZA9003)
Number of subjects: 180
Study 23813113 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifocal intraocular lenses with diffractive optics and aspheric profiles
Number of subjects: 180
Study 23813113 — intervention group
Group type: EXPERIMENTAL
Intervention: Refractive, distance dominant lens designs
Number of subjects: 180
Study 23377515 — intervention group
Group type: EXPERIMENTAL
Intervention: High-potency, multimechanism skin care regimen (NeoStrata® Skin Active)
Number of subjects: 0
Study 23377515 — intervention group
Group type: COMPARATOR
Intervention: Vehicle control
Number of subjects: 0
Study 20712131 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of oral activated charcoal (50 g) given 30 min after drugs
Number of subjects: 6
Study 20712131 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of oral activated charcoal (20 g) given 6-72 h after LTG
Number of subjects: 6
Study 20712131 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated doses of oral activated charcoal (20 g) given 12-48 h after OXC
Number of subjects: 6
Study 18466657 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-sodium, high-potassium diet (LNAHK)
Number of subjects: 94
Study 18466657 — intervention group
Group type: EXPERIMENTAL
Intervention: High-calcium diet (HC)
Number of subjects: 94
Study 18466657 — intervention group
Group type: COMPARATOR
Intervention: Moderate-sodium, high-potassium, high-calcium Dietary Approaches to Stop Hypertension (DASH) diet (OD)
Number of subjects: 94
Study 18466657 — intervention group
Group type: COMPARATOR
Intervention: Control diet (CD)
Number of subjects: 94
Study 15888425 — intervention group
Group type: EXPERIMENTAL
Intervention: CAST plus vocational rehabilitation
Number of subjects: 138
Study 15888425 — intervention group
Group type: EXPERIMENTAL
Intervention: TSSN plus vocational rehabilitation
Number of subjects: 138